MYCN and neuroblastoma: BCL-2 is expressed significantly higher in neuroblastoma cells compared with other solid cancer lines, whilst BCL-XL expression is reduced, consistent with their responsiveness to Venetoclax and Navitoclax when MYCN is amplified [48–51].